Catalent, Inc.
catalent.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed Nov 5, 2024. Its latest SEC filing is a 15-12G from Dec 30, 2024.
10-Q for Q1 FY2025, filed Nov 5, 2024
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops and manufactures drugs, biologics, and consumer health products for pharmaceutical, biotechnology, and consumer health companies.
10-K for FY2024, filed Sep 6, 2024
How Did They Make Money?
Customers pay a fixed price per unit for commercial product supply as products pass required quality checks, and fixed fees for development and clinical-supply work, usually as the work is performed. Invoices are typically due 30 to 45 days after billing.
10-K for FY2024, filed Sep 6, 2024Manufacturing and commercial product supply revenue consists of revenue earned by manufacturing products supplied to customers under…View ↗
Development services contracts generally take the form of short-term, fee-for-service arrangements. Performance obligations vary, but…View ↗
The Company measures progress toward the completion of its performance obligations satisfied over time based on the nature of the services…View ↗
Where multiple performance obligations exist in a single contract, the Company allocates consideration to each performance obligation using…View ↗
$4.4B
-
10-K for FY2024, filed Sep 7, 2024
$4.4B ↗
Who Were Their Customers?
Catalent sells directly to pharmaceutical, biotechnology, and consumer health companies, including large firms and emerging and specialty businesses, for development and marketed-product needs.
10-K for FY2024, filed Sep 6, 2024
10-K for FY2024, filed Sep 6, 2024
For the fiscal years ended June 30, 2024, 2023, and 2022 the Company had one customer that accounted for 16%, 10% and 10%, respectively, of…View ↗
Did Revenues Turn Into Profits?
No. It lost $1B in FY2024.
10-K for FY2024, filed Sep 7, 2024
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed Nov 6, 2024
−$129MView ↗
- ▼ −83% (Loss)
- vs −$759M in Q1 FY2024
-
Dec 18, 2024
Novo Holdings completed its acquisition of Catalent
Catalent's shares stopped trading on the NYSE; Novo Nordisk was to acquire three fill-finish sites and related assets from Novo Holdings.
Sources
8-K, filed Dec 18, 2024
SOMERSET, NJ and COPENHAGEN, Denmark – December 18, 2024 – Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of…View ↗
Consumer-health formats
Catalent expanded its consumer-health offerings through Bettera, adding gummy and soft-chew formats to its product range.
10-K for FY2021, filed Aug 30, 2021 10-K for FY2024, filed Sep 6, 2024OverviewView ↗
Loading...
